Results 221 to 230 of about 125,041 (360)

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

open access: yesThe Journal of Pathology, EarlyView.
Abstract Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy.
Jouni Härkönen   +14 more
wiley   +1 more source

Safety and efficacy of a feed additive consisting of a proanthocyanidin-rich dry extract from the fruit of <i>Vaccinium macrocarpon</i> Aiton (cranberry extract) for dogs and cats (ACEL pharma S.r.l.). [PDF]

open access: yesEFSA J
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)   +26 more
europepmc   +1 more source

Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Objective In‐utero cell and gene therapies may offer prenatal treatment options for inherited diseases. Preclinical data suggests in‐utero (IU) hematopoietic stem cell transplantation (HSCT) could prevent Fanconi anemia (FA) related bone marrow failure without genotoxic conditioning or immune suppression.
Tony Lum   +4 more
wiley   +1 more source

Nanosuspensions Loaded with Acetogenins: Physical Stability During In Vitro Digestion, Genotoxicity and Cytotoxicity. [PDF]

open access: yesFoods
López-Romero BA   +5 more
europepmc   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde   +4 more
wiley   +1 more source

Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review

open access: yesPhytotherapy Research, EarlyView.
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley   +1 more source

Home - About - Disclaimer - Privacy